BCM
PVLA

BML Capital Management’s Palvella Therapeutics PVLA Stock Holding History

BML Capital Management’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-42,130
Closed -$506K – 29
2024
Q4 		$506K Hold
42,130
– – 0.31% 18
2024
Q3 		$699K Buy
+42,130
New +$616K 0.41% 21

Other funds holding PVLA

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

BML Capital Management's PVLA Position: Q1 2025 in Review

BML Capital Management sold out of Palvella Therapeutics (PVLA) in Q1 2025, closing a stake of 42,130 shares — an estimated $506K sold.

BML Capital Management first reported a position in PVLA in Q3 2024 and held it in 2 quarters. The position peaked at $699K in Q3 2024. 41 funds tracked by Wall St. Rank hold PVLA as of Q1 2025.

  • BML Capital Management reported no remaining Palvella Therapeutics position as of Q1 2025 after selling out during the quarter.
  • BML Capital Management sold 42,130 Palvella Therapeutics shares in Q1 2025, an estimated $506K.
  • BML Capital Management first reported a position in Palvella Therapeutics in Q3 2024 and held it in 2 quarters.
  • BML Capital Management's Palvella Therapeutics position peaked at $699K in Q3 2024.
  • 41 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2025.

Based on BML Capital Management's 13F filing for Q1 2025, filed 7 May 2025.